Emanuela Palmerini
@ManuPalmerini
Followers
273
Following
2K
Statuses
253
Joined February 2013
Discussing on ultra -rare sarcoma in beautiful Tokyo! #ctos2019 #meeting #sarcoma #travelling #tokyo #friends #research #japanesefriends @ Shinjuku Tokyo,Japan (日本东京，新宿）
0
1
10
Grateful to Filippo family and #iosonofilippo patient advocacy to support @IRCCS_Rizzoli #research for #osteosarcoma and perpetuate Filippo memory! #sarcoma #research @FosterConsorti1 @AgentsMIB @OSInstitute
0
0
4
RT @ItaSarcomaGroup: 📣Giovedì 30 gennaio alle ore 13.30 su #Rai2 , nella rubrica del Tg2🟥"Tutto il bello che c'è" andrà in onda un servizio…
0
6
0
RT @isidrolauscher: Most excited to see our study presenting the mechanism driving ~50% of osteosarcomas (LTA #chromothripsis) out in @Cell…
0
49
0
Thanks @GreekSarc and @FosterConsorti1 for the opportunity to present the #fosfer-cabos trial! #ostesarcoma #canozantinib @IRCCS_Rizzoli
@ManuPalmerini sharing with us the #FOSTER consortium formed to champion #osteosarcoma research throughout #Europe 🇪🇺. #collaborations remains key to move the field forward together. @GreekSarc #masterclass
1
0
6
RT @herbloong: Kicking off the @GreekSarc #sarcoma #masterclass in #Athens is @WTapMD of @MSKCancerCenter taking us through his insights on…
0
1
0
RT @herbloong: The last #conference of the year done and dusted! Thanks 🇬🇷 @GreekSarc esp. @AKyriazoglou this wonderful invitation! An am…
0
4
0
RT @herbloong: #Sarcoma educational session focusing on treatment of various types including #liposarcoma, #desmoid, #ASPS and #chondrosarc…
0
8
0
RT @oncodaily: Challenges and Opportunities in Studying Rare Cancers Amy K. O’Sullivan highlights how biomarker-driven oncology is reshapi…
0
14
0
#Bonetumors: With #nivolumab and #sunitinib 6 months PFSR 42% and responses observed in 1/4 patients with #dedifferentiatedchondrosarcoma and 1/17 pts with #osteosarcoma! Thanks to @gruposgeis and @ItaSarcomaGroup for thie effort! @irrcsrizzoli @ctos
0
1
1
#Bonetumors: With #nivolumab and #sunitinib 6 months PFSR 42% and responses observed in 1/4 patients with #dedifferentiatedchondrosarcoma and 1/17 pts with #osteosarcoma! Thanks to @gruposgeis and @ItaSarcomaGroup for thie effort! @irrcsrizzoli @ctos
0
5
6
@ProfDMThomas congrats!
Huge Kudos to David! So grateful to know him as a friend, colleague, and scientist. His brilliant intellect admixed with his inclusivity make him truly remarkable. TY for everything @ProfDMThomas @ballingermandy @ctosociety @UCDavisOrtho @UCD_Cancer @UCDavisMed @UofCAHealth
1
0
1
RT @JTrentMDPhD: #Liposarcoma : Epidemiology, Diagnosis, Pathophysiology, and Limitations of Current Therapies @EmilyJonczak 1,2,†, Julie…
0
18
0
0
0
6
RT @RLRandallMD: Kudos to Robert Maki,MD,past President of @ctos, an extraordinary person & med onc for giving the annual Nina Axelrad Lect…
0
11
0
RT @JTrentMDPhD: Palbociclib does not increase activity of temozolomide plus irinotecan in Ewing #Sarcoma #ctos2024. Is it harmful? https:/…
0
5
0
RT @ctosociety: With >1000 participants and >500 abstracts presented - #CTOS2024 is the biggest platform connecting anyone interested in sa…
0
19
0
0
5
0
Well deserved maestro! #CTOS2024 #mentor #sarcoma #Immunology @ItaSarcomaGroup @ctosociety @MSKCancerCenter @setolae
0
0
6